BCEL Atreca Inc.

14.31
-0.16  -1%
Previous Close 14.47
Open 14.49
Price To Book 1.95
Market Cap 400,118,747
Shares 27,960,779
Volume 343,267
Short Ratio
Av. Daily Volume 85,251
Stock charts supplied by TradingView

NewsSee all news

  1. Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101

    First IND clearance of a clinical candidate derived from Atreca's differentiated drug discovery platform  Phase 1b clinical trial in patients with solid tumors to begin in early 2020 REDWOOD CITY, Calif.,

  2. Atreca to Present at Two Upcoming Investor Conferences

    REDWOOD CITY, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response,

  3. Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response,

  4. Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b trial to be initiated early 2020.
ATRC-101
Solid tumors

Latest News

  1. Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101

    First IND clearance of a clinical candidate derived from Atreca's differentiated drug discovery platform  Phase 1b clinical trial in patients with solid tumors to begin in early 2020 REDWOOD CITY, Calif.,

  2. Atreca to Present at Two Upcoming Investor Conferences

    REDWOOD CITY, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response,

  3. Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response,

  4. Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response,